PPMD to provide grant to clinical sites participating in Phase 2 study of ACE-031

Funds Will Help Offset Travel Costs for Participants

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced that PPMD will provide a grant to clinical sites participating in Acceleron Pharma's Phase 2 clinical study of ACE-031.  These grants will help patients' families cover travel costs to and from the study site, and hotel rooms and meals during study visits.  The first two grants have been awarded to Alberta Children's Hospital and McMaster University.

Earlier this year, Cambridge, MA-based biotechnology company Acceleron launched a Phase 2 clinical study in Canada of ACE-031, a drug that promotes muscle growth. Previous studies in healthy volunteers have demonstrated that the drug increases lean mass and favorably affects markers of fat and bone mass.

The ACE-031 Phase 2 study is currently enrolling patients. Participants must be at least four years old and still walking. Additional details are available on Acceleron's website: www.acceleronpharma.com and at Clinicaltrials.gov (refer to study identifier NCT01099761).

Ms. Furlong explained the reason for PPMD's support of the ACE-031 trial with these grants. "When a family makes the decision to allow their child to participate in a clinical trial, they are making a huge decision. They are placing the health of their child in the hands of the researchers behind the project and they are allowing their child to take risks that will hopefully benefit the entire Duchenne community. We feel strongly in the work that Acceleron is doing and we wanted to help the study sites help the participating families, so that financial stresses are not added to the laundry list of things they have to worry about. The researchers behind these clinical trials are not the only pioneers in Duchenne – support must be given to the young people who participate."  

Duchenne, the most common form of childhood muscular dystrophy, is a progressive and fatal muscle disorder affecting boys and young men that causes the loss of muscle function, wheelchair dependency and a decline in respiratory and cardiac function.  

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients